TY  -  JOUR
AU  -  Giuliani, Jacopo
AU  -  Bonetti, Andrea
T1  -  Immunotherapy in first-line for advanced non-small 
cell lung cancer: <br>a cost-effective choice?
PY  -  2019
Y1  -  2019-03-01
DO  -  10.1701/3132.31141
JO  -  Recenti Progressi in Medicina
JA  -  Recenti Prog Med
VL  -  110
IS  -  3
SP  -  138
EP  -  143
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-1840
Y2  -  2026/04/15
UR  -  http://dx.doi.org/10.1701/3132.31141
N2  -  Summary. Introduction. The present evaluation was restricted to pivotal phase III randomized controlled trials (RCTs) in first-line for metastatic non-small cell lung cancer (NSCLC). Materials and methods. We calculated the pharmacological costs necessary to get the benefit in overall survival (OS), for each trial. Results. Our analysis evaluated 10 phase III RCTs, including 9485 patients. The most relevant increase of cost € per month of OS-gain was associated with bevacizumab (66,720 €) and the lowest with the use of pembrolizumab (2734 €). Conclusion. Combining pharmacological costs of drugs with the measure of efficacy represented by OS, pembrolizumab is a cost-effective first-line treatment for patients with metastatic NSCLC.
ER  -